One-year efficacy and safety of saxagliptin add-on in patients receiving dapagliflozin and metformin

Diabetes, Obesity and Metabolism

Volumn 18, Issue 11, 2016, Pages 1128-1133

  Matthaei, S ^a   Aggarwal, N ^b   Garcia Hernandez, P ^c   Iqbal, N ^d   Chen, H ^d   Johnsson, E ^e   Chin, A ^d   Hansen, L ^f  

^a Quakenbrück Hospital   (Germany)

^b Aggarwal and Associates Ltd   (Canada)

^c HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

^d ASTRAZENECA   (United Kingdom)

^e ASTRAZENECA R AND D   (Sweden)

^f BRISTOL MYERS SQUIBB   (United States)

Author keywords

dapagliflozin; DPP 4 inhibitor; metformin; SGLT 2 inhibitor; type 2 diabetes

Indexed keywords

DAPAGLIFLOZIN; HEMOGLOBIN A1C; METFORMIN; PLACEBO; SAXAGLIPTIN; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ADAMANTANE; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; DIPEPTIDE; GLUCOSE BLOOD LEVEL; GLUCOSIDE; GLYCOSYLATED HEMOGLOBIN;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GENITAL TRACT INFECTION; GLYCEMIC CONTROL; HEADACHE; HEART FAILURE; HUMAN; HYPERSENSITIVITY; HYPOGLYCEMIA; HYPOTENSION; KIDNEY FAILURE; LIVER DISEASE; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ADENOCARCINOMA; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SKIN DISEASE; URINARY TRACT INFECTION; WEIGHT REDUCTION; AGED; ANALOGS AND DERIVATIVES; BLOOD; BODY WEIGHT; CHEMICALLY INDUCED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; TREATMENT OUTCOME;

ADAMANTANE; ADULT; AGED; BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DIPEPTIDES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GLUCOSIDES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84990216150     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12741     Document Type: Article

References (21)

1. Handelsman Y, Bloomgarden ZT, Grunberger G, et al. American Association of Clinical Endocrinologists and American College of Endocrinology clinical practice guidelines for developing a diabetes mellitus comprehensive care plan-2015. Endocr Pract. 2015;21:1–87.
2. Mazzola N. Review of current and emerging therapies in type 2 diabetes mellitus. Am J Manag Care. 2012;18:S17–S26.
3. Nauck MA, El-Ouaghlidi A. The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1. Diabetologia. 2005;48:608–611.
4. Nauck MA. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Des Devel Ther. 2014;8:1335–1380.
5. Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm–2016 Executive Summary. Endocr Pract. 2016;22:84–113.
6. American Diabetes Association. Approaches to glycemic treatment. Diabetes Care. 2016;39:S52–S59.
7. Matthaei S, Catrinoiu D, Celinski A, et al. A randomized, double-blind trial of triple therapy with saxagliptin add-on to dapagliflozin plus metformin in patients with type 2 diabetes. Diabetes Care. 2015;11:2018–2024.
8. Zhang M, Tsiatis AA, Davidian M. Improving efficiency of inferences in randomized clinical trials using auxiliary covariates. Biometrics. 2008;64:707–715.
9. Tsiatis AA, Davidian M, Zhang M, Lu X. Covariate adjustment for two-sample treatment comparisons in randomized clinical trials: a principled yet flexible approach. Stat Med. 2008;27:4658–4677.
10. DeFronzo RA, Lewin A, Patel S, et al. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care. 2015;38:384–393.
11. Rosenstock J, Hansen L, Zee P, et al. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care. 2015;38:376–383.
12. Herrera Marmolejo M, Mathieu C, Gonzalez Gonzalez J, et al. Triple therapy with dapagliflozin add-on to saxagliptin plus metformin over 52 weeks in patients with type 2 diabetes (A306). The 5th World Congress on Controversies to Consensus in Diabetes, Obesity, and Hypertension (CODHy); November 5-7 2015; Istanbul, Turkey.
13. U.S. Food and Drug Administration. FDA drug safety communication: FDA warns that DPP-4 inhibitors for type 2 diabetes may cause severe joint pain. 2015. http://www.fda.gov/Drugs/DrugSafety/ucm459579.htm. Accessed May 19, 2016.
14. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317–1326.
15. Zannad F, Cannon CP, Cushman WC, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015;385:2067–2076.
16. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140–149.
17. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
18. Neal B, Perkovic V, de Zeeuw D, et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)–a randomized placebo-controlled trial. Am Heart J. 2013;166:217–223, e211.
19. Multicenter trial to evaluate the effect of dapagliflozin on the incidence of cardiovascular events (DECLARE-TIMI58). 2015. http://clinicaltrials.gov/ct2/show/NCT01730534?term=declare&rank=2. Accessed May 19, 2016.
20. FDA Drug Safety Communication. FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. 2015. http://www.fda.gov/Drugs/DrugSafety/ucm446845.htm. Accessed May 19, 2016.
21. American Association of Clinical Endocrinologists. AACE/ACE scientific and clinical review: association of SGLT2 inhibitors and DKA. 2015. http://resources.aace.com/in-the-news/aaceace-scientific-and-clinical-review-association-sglt2-inhibitors-and-dka. Accessed May 19, 2016.